Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals CALGARY and LAVAL, QC

Sundial and Crescita Sign Exclusive Partnership

to Develop Cannabis and Hemp Topicals

CALGARY and LAVAL, QC, Oct. 28, 2019 /CNW/

- Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial"), a Canadian licensed producer of cannabis and Crescita Therapeutics

Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita"), a Canadian commercial dermatology company, today announced a development

and licensing agreement (the "Agreement") granting Sundial the worldwide rights to Crescita's proprietary transdermal

delivery technologies for the development of topicals containing cannabis and hemp.

The partnership combines Crescita's leading

expertise in dermal sciences and in the development of patented topical formulations with Sundial's cannabis production, extraction

and commercialization expertise. The Agreement will enable the development of unique, high-quality cannabis and hemp topicals for

the Canadian and international non-prescription markets.

"Partnering with a world-class dermatology

company like Crescita is a significant step for Sundial as we continue to stay on top of consumer trends in the cannabis industry

and prepare for expanded global reach," said Brian Harriman, COO of Sundial. "This partnership is a key component of

our international CBD strategy across Canada, Europe, the United States and future jurisdictions, allowing us to provide effective

and safe branded products based on differentiated intellectual property ("IP") that consumers can trust."

Pursuant to the Agreement, Crescita will develop

formulations for topical cannabis and hemp products using its patented transdermal delivery technologies: Multiplexed Molecular

Penetration Enhancers ("MMPE") and DuraPeel ("DuraPeel"). Based on a study conducted in 2018,

MMPE and DuraPeel both showed significantly increased skin absorption of cannabidiol ("CBD") by up to 14- and 6-fold,

respectively, when compared to the control formulation.

"We are thrilled to establish this important

partnership with Sundial, a visionary in crafting premium cannabis brands and a company that shares our passion for innovation,"

said Serge Verreault, President and CEO of Crescita. "This milestone underscores the strength of our IP and technologies in

providing a differentiating factor in the cannabis market and is a step forward in making Crescita a leading dermatology company."

Sundial will fund the development and

formulation costs and will have the worldwide marketing and distribution rights for the newly developed products. In addition,

Sundial will support Crescita in applying for and obtaining the Health Canada Standard Processing License for Cannabis. Crescita

will receive tiered royalties on the net worldwide sales of these products, and retains the right to leverage its IP for future

product development under its own brands.

Sundial's partnership with Crescita creates

strong synergies across its multiple partnership agreements, including its skin disease and anti-aging patents with PathwayRx.

Sundial's initial topical offerings will include a CBD-infused roll-on and topical cream that will utilize the MMPE technology

to deliver faster skin penetration without irritation. Both products are expected to be available for purchase in early 2020.

About Sundial Growers Inc.

Sundial proudly crafts pioneering cannabis brands to Heal, Help and Play:

Heal - cannabis products used as prescription medicine

Help - cannabis products that strive to promote health

and wellness through CBD

Play - cannabis products to enhance social, spiritual and

recreational occasions

Sundial has facilities in Canada and the United

Kingdom and provides quality and consistent products consumers can trust.

In Canada, we grow 'craft-at-scale' cannabis

using purpose-built modular facilities and award-winning genetics. Sundial's flagship production facility is located in Olds, Alberta

with a second facility in Rocky View, Alberta. We have commenced construction of our next purpose-built facility in Merritt, British

In the United Kingdom, we grow high-quality

traceable plants, including hemp, ornamental flowers and edible herbs, in over 1.5 million square feet of state-of-the-art environmentally

friendly, indoor facilities. Bridge Farm has three facilities in Spalding with another currently under construction.

We employ nearly 1,000 employees globally,

full-time and seasonal, bringing economic benefits to the local communities in which we operate.

For more information about Sundial, visit www.sndlgroup.com

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with manufacturing capabilities

and a portfolio of non-prescription skincare products for the treatment and care of skin conditions, diseases and their symptoms

and prescription drug products for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support

the development of patented formulations that can facilitate the delivery of active drugs into or through the skin.

Supported by a sales force covering all of

Canada, and executing its business to business to consumer marketing approach, Crescita sells its non-prescription products through

spas, medispas and medical clinics.

In addition, our brands and formulations are

currently sold in the U.S. and Asian markets through international distributors and through a cross-border e-commerce channel.

Crescita developed a prescription product call

Pliaglis that utilizes our proprietary phase-changing topical cream Peel technology. Pliaglis is a topical local

anaesthetic cream that provides safe and effective local dermal analgesia on intact skin prior to superficial dermatological procedures.

The product is currently licensed to two pharmaceutical companies.

Crescita also provides contract development

and manufacturing services to several local and North American clients. Our contract development and manufacturing organization

infrastructure allows Crescita to provide its clients with development and other support activities required to bring their products

to market. Crescita has extensive expertise in product formulation and development, leveraging our patented transdermal delivery

technologies, and specializes in manufacturing creams, liquids, gels ointments and serums. The Company operates out of a 50,000

square-foot manufacturing facility located in Laval, Qu bec, and is compliant with current Canadian Good Manufacturing Practices

and is regularly inspected by Health Canada.

The MMPE technology uses synergistic combinations of certain pharmaceutical excipients included on the FDA's Inactive Ingredient

Guide for improved topical delivery of active pharmaceutical ingredients (APIs) into or through the skin. The benefits of

this technology include the potential for increased penetration of APIs with the possibility of improved efficacy, lower API concentration

and/or reduced dosing. Issued U.S. patents provide intellectual property protection through March 6, 2027.

The DuraPeel technology is a self-occluding, film-forming cream/gel formulation that provides extended release delivery to

the site of application. The cream/gel contains a drug applied to a patient's skin forming a pliable layer that releases drug into

the skin for up to 12 hours. The benefits of the DuraPeel technology include proven compatibility with a variety of active pharmaceutical

ingredients ("APIs"). A self-occluding film reduces product transference risk, provides fast drying time, facilitates

easy application and removal, and enables application to large and irregular skin surfaces. Patents have been issued in Australia, Canada, Japan and

the U.S. with the latest expiry in 2027. The European patent application is still pending.

Email: ir@crescitatx.com

Tel: 1.905.326.1888, extension 10

Email: glen@bristolir.com

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain "forward-looking information" within the meaning of applicable

securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such

as "plan", "continue", "expect", "project", "intend", "believe", "anticipate",

"estimate", "may", "will", "potential", "proposed" and other similar words, or

statements that certain events or conditions "may" or "will" occur. These statements are only predictions.

Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements

throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the

statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or

results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly

disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information,

future events or otherwise, except as expressly required by applicable law.

Crescita Therapeutics (CNW Group/Sundial Growers

View original content to download multimedia:http://www.prnewswire.com/news-releases/sundial-and-crescita-sign-exclusive-partnership-to-develop-cannabis-and-hemp-topicals-300946077.html